Results 131 to 140 of about 48,174 (231)

Incremental cost-effectiveness ratios (ICER, in USD/QALY).

Incremental cost-effectiveness ratios (ICER, in USD/QALY).
Chanchai Charonpongsuntorn (18196364), Tawesak Tanwandee (279135), Wattana Sukeepaisarnjaroen (279136), Wantanee Kulpeng (744964), Pisit Tangkijvanich (513614), Witthawat Pantumongkol (18196361), Supachaya Sriphoosanaphan (9533104), Abhasnee Sobhonslidsuk (840642)   +7 more
core   +1 more source

The impact of willingness-to-pay threshold on price reduction recommendations for oncology drugs: a review of assessments conducted by the Canadian Agency for Drugs and Technologies in Health

Journal of Comparative Effectiveness Research
Since late 2020, the Canadian Agency of Drugs and Technologies in Health (CADTH) has been using a threshold of $50,000 (CAD) per quality-adjusted life-year (QALY) for both oncology and non-oncology drugs. When used for oncology products, this threshold
Chakrapani Balijepalli, Lakshmi Gullapalli, Juhi Joshy, Nigel SB Rawson   +3 more
doaj   +1 more source

Immune checkpoint inhibitors-based therapies for first-line treatment of advanced ovarian cancer with non-BRCAm/HRD-negative: a cost-effectiveness analysis

Journal of Ovarian Research
Background Emerging evidence supports the clinical potential of immune checkpoint inhibitors (ICIs) with or without bevacizumab and poly-(adenosine diphosphate-ribose) polymerase (PARP) inhibitors for refractory advanced ovarian cancer (AOC) with BRCA ...
Youwen Zhu, Xiaofang Zhou, Kun Liu, Hong Zhu   +3 more
doaj   +1 more source

Toward a Consensus on the QALY

Качественная клиническая практика, 2018
.
Michael Drummond, Diana Brixner, Marthe Gold, Paul Kind, Alistair Mcguire, Erik Nord, I. A. Vilum, D. Yu. Belousov   +7 more
doaj  

Gute Qalys, schlechte Qalys? [PDF]

Gesundheits- und Sozialpolitik, 2007
openaire   +1 more source

Cost-effectiveness of iStent-based trabecular micro-bypass stenting combined with cataract surgery in mild-to-moderate open-angle glaucoma: a systematic review of analytic perspectives and time horizons. [PDF]

Cost Eff Resour Alloc
Drobin D.
europepmc   +1 more source

Cost-effectiveness of newborn screening for phenylketonuria and congenital hypothyroidism in Hubei, China. [PDF]

BMJ Open
Wang B, Zhang H, Xia Y, Liu X, Wu Q, Song J, Han J, Ning K.   +7 more
europepmc   +1 more source

Systematic review of cost-effectiveness analyses of weight loss interventions for knee osteoarthritis. [PDF]

BMJ Open
Gao Y, Mistry H, Dhaif F, Mcmurray B, Susarla S, Naghdi S.   +5 more
europepmc   +1 more source

Cost-effectiveness of aficamten for obstructive hypertrophic cardiomyopathy: a model-based analysis from the perspective of the Chinese healthcare system. [PDF]

Front Pharmacol
Zhai F, Li H, Jiang C, Mao J, Chen J, You C.   +5 more
europepmc   +1 more source

Manufacturing cost analysis and exploratory economic evaluation of natural killer cell immunotherapy for paediatric solid tumors. [PDF]

Clin Transl Immunology
Wahid ST, Elliott M, Wang Y, Nicholls W, Omer N, Souza-Fonseca-Guimaraes F, Tuffaha H.   +6 more
europepmc   +1 more source